Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009.
暂无分享,去创建一个
R. Labianca | J. Berlin | K. Haustermans | E. Van Cutsem | B. Nordlinger | T. Gruenberger | N. Pavlidis | M. Ducreux | H. Lenz | J. Tabernero | A. Grothey | D. Haller | F. Ciardiello | P. Rougier | N. Arber | W. Schmiegel | A. Ohtsu | B. Minsky | B. Glimelius | A. de Gramont | A. Gramont | A. Cervantes | H. Schmoll | E. Díaz-Rubio | A. Sobrero | C. J. van de Velde | P Rougier | M Ducreux | H J Lenz | R Labianca | A Sobrero | N Pavlidis | A. Grothey | A Grothey | E Van Cutsem | A Cervantes | B Nordlinger | N Arber | R. Geva | W Schmiegel | B Glimelius | H J Schmoll | A Ohtsu | F Ciardiello | J Tabernero | K Haustermans | M Dicato | J Berlin | A De Gramont | E Diaz-Rubio | R Geva | R Glynne Jones | T Gruenberger | D Haller | B Minsky | C Van de Velde | M. Dicato | C. Velde | Wolff Schmiegel | E. Cutsem | R. Geva | R. Glynne Jones | R. Jones | W. Schmiegel
[1] C. Erlichman,et al. Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. , 1992, European journal of cancer.
[2] H. McLeod,et al. UGT1A and irinotecan toxicity: keeping it in the family. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Jun Liang,et al. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer , 2010, Cancer Chemotherapy and Pharmacology.
[4] J. Vandesompele,et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] A Messori,et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. , 2001, The New England journal of medicine.
[6] M. Roh,et al. Prognostic Value of ERCC1, Thymidylate Synthase, and Glutathione S-Transferase &pgr; for 5-FU/Oxaliplatin Chemotherapy in Advanced Colorectal Cancer , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] S. Gruber,et al. Microsatellite instability in colorectal cancer—the stable evidence , 2010, Nature Reviews Clinical Oncology.
[8] Dongsheng Tu,et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.
[9] V. Catalano,et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Ferlay,et al. Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] F. Lévi,et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] C. Tournigand,et al. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] L. Crinò,et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M. Roh,et al. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. , 2009, American journal of clinical oncology.
[15] D. Cunningham,et al. The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] B. Giraudeau,et al. ERCC1 Codon 118 Polymorphism Is a Predictive Factor for the Tumor Response to Oxaliplatin/5-Fluorouracil Combination Chemotherapy in Patients with Advanced Colorectal Cancer , 2005, Clinical Cancer Research.
[17] L. Saltz,et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.
[18] R. Simes,et al. High epiregulin (EREG) gene expression plus K-ras wild-type (WT) status as predictors of cetuximab benefit in the treatment of advanced colorectal cancer (ACRC): Results from NCIC CTG CO.17-A phase III trial of cetuximab versus best supportive care (BSC). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] E. Guinó,et al. Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. , 2008, European journal of cancer.
[20] F. Kabbinavar,et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. , 2007, Journal of the National Cancer Institute.
[21] R. Gafà,et al. Microsatellite Instability and Colorectal Cancer Prognosis , 2005, Clinical Cancer Research.
[22] S. Culine,et al. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure , 2000, British Journal of Cancer.
[23] D. Lacombe,et al. EORTC Elderly Task Force experts' opinion for the treatment of colon cancer in older patients. , 2010, Cancer treatment reviews.
[24] Shenhong Wu,et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. , 2008, JAMA.
[25] D. Sargent,et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Cockcroft Dw,et al. Prediction of Creatinine Clearance from Serum Creatinine , 1976 .
[27] P. Vreken,et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] R. Labianca,et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.
[29] S. Veronese,et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] A. Jemal,et al. Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.
[31] Thomas J. Smith,et al. Taking action on the volume-quality relationship: how long can we hide our heads in the colostomy bag? , 2003, Journal of the National Cancer Institute.
[32] D. Cunningham,et al. Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. , 1997, British Journal of Cancer.
[33] A. Giatromanolaki,et al. Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer , 2005, Clinical & Experimental Metastasis.
[34] P. Murawa,et al. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] S. Tejpar,et al. 6005 PIK3CA, BRAF and KRAS mutations and outcome prediction in chemorefractory metastatic colorectal cancer (mCRC) patients treated with EGFR targeting monoclonal antibodies (MoAbs): results of a European Consortium , 2009 .
[36] E. Demidenko,et al. Influence of NCI Cancer Center Attendance on Mortality in Lung, Breast, Colorectal, and Prostate Cancer Patients , 2009, Medical care research and review : MCRR.
[37] J. Meyerhardt,et al. KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803 , 2009, Clinical Cancer Research.
[38] R. Houlston,et al. Systematic review of microsatellite instability and colorectal cancer prognosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] B. Hillner,et al. Ensuring quality cancer care by the use of clinical practice guidelines and critical pathways. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] C. Tournigand,et al. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] F.A.M. Bordonaba,et al. Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer , 2009 .
[42] S. Culine,et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] J. Horiot,et al. Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[44] F. Cavalli,et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients , 2007, British Journal of Cancer.
[45] P. Loehrer. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial , 2008 .
[46] K. Syrigos,et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG) , 2006, British Journal of Cancer.
[47] P. Bycott,et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study , 2008, The Lancet.
[48] K. Kinzler,et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status , 2002, Nature.
[49] M. Lishner,et al. Bevacizumab treatment for cancer patients with cardiovascular disease: a double edged sword? , 2008, European heart journal.
[50] N. Kemeny,et al. Prognostic factors in advanced colorectal carcinoma. Importance of lactic dehydrogenase level, performance status, and white blood cell count. , 1983, The American journal of medicine.
[51] S. Bull,et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. , 2000, The New England journal of medicine.
[52] E. Van Cutsem,et al. Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[53] Sabine Tejpar,et al. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC , 2009, Nature Reviews Clinical Oncology.
[54] Y. Humblet,et al. Cetuximab dose-escalation study in patients with metastatic colorectal cancer with no or slight skin reactions on cetuximab dose treatment (EVEREST): pharmacokinetic and efficacy data of a randomized study. , 2007 .
[55] L. Saltz,et al. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. , 2001, The oncologist.
[56] Seta Shahin,et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] R. Stephens,et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] R. Wolff,et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. , 2005, Cancer research.
[59] A. V. van Kuilenburg,et al. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. , 2002, Pharmacogenetics.
[60] R. Pearson,et al. Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer , 2010 .
[61] A. Lièvre,et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.
[62] F. Goldwasser,et al. Hypertension as a surrogate marker for the activity of anti-VEGF agents. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[63] W. Scheithauer,et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[64] H. Blomgren,et al. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] Daniel J Sargent,et al. Clinical trial designs for predictive marker validation in cancer treatment trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] Marc Peeters,et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] Richard J Stephens,et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial , 2007, The Lancet.
[68] L. Påhlman,et al. Determinants of prognosis in advanced colorectal cancer. , 1991, European journal of cancer.
[69] Joseph G Ibrahim,et al. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. , 2007, Journal of the National Cancer Institute.
[70] F. Ciardiello,et al. Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data , 2007 .
[71] S. Curley,et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. , 2009, JAMA.
[72] B. Reigner,et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients , 2002, Cancer Chemotherapy and Pharmacology.
[73] J. Primrose,et al. The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer. , 1993, British Journal of Cancer.
[74] Sabine Tejpar,et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] P. Lavin,et al. Survival and response to chemotherapy for advanced colorectal adenocarcinoma. An eastern cooperative oncology group report , 1980, Cancer.
[76] I. Iwanicki-Caron,et al. Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[77] F. Baas,et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[78] K. Itoh,et al. Factors Affecting the Pharmacokinetics of CPT-11: The Body Mass Index, Age and Sex are Independent Predictors of Pharmacokinetic Parameters of CPT-11 , 2004, Investigational New Drugs.
[79] Linda Mol,et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. , 2009, The New England journal of medicine.
[80] Shuji Ogino,et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer , 2008, Gut.
[81] D. Sargent,et al. Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard? , 2007, The Lancet.
[82] M. Salto‐Tellez,et al. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[83] R. Schilsky,et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[84] R. Berardi,et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[85] J. Grem. The prognostic importance of tumor markers in adenocarcinomas of the gastrointestinal tract. , 1997, Current opinion in oncology.
[86] C. Bokemeyer,et al. Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. , 2010 .
[87] S. Groshen,et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[88] N. Funel,et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[89] S. Andreola,et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[90] D. Lambrechts,et al. The role of KRAS, BRAF, NRAS, and PIK3CA mutations as markers of resistance to cetuximab in chemorefractory metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] J. Kirkwood,et al. Effect of TKI258 on plasma biomarkers and pharmcokinetics in patients with advanced melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[92] G. Fontanini,et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer , 2009, British Journal of Cancer.
[93] I. Nagtegaal,et al. Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. , 2009, European journal of cancer.
[94] L. Mazzucchelli,et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[95] Shung-Haur Yang,et al. Carcinoembryonic antigen in monitoring of response to systemic chemotherapy in patients with metastatic colorectal cancer , 2001, International Journal of Colorectal Disease.
[96] E. Van Cutsem,et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[97] Cristián Zegers Ariztía,et al. Manual , 2002 .
[98] G. Tortora,et al. EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.